Single Molecule DNA and RNA Sequencing to Detect Residual Cancer and Clonal Hematopoiesis

Innovative Discoveries Series

Dr. Todd Druley will discuss novel strategies for single molecule DNA and RNA sequencing as a modality for characterization of clonal hematopoiesis and minimal residual disease (MRD) detection in cancer. Despite “deep sequencing,” next-generation platforms have an error rate of 0.5-1.0%, precluding straightforward sequencing for MRD, which requires sensitivity of <1:1,000. However, using a single molecule labeling strategy to correct sequencing errors, the Druley lab has published multiple studies identifying rare clonal mutations at levels as low as 1:10,000 from heterogenous DNA samples. His group is now moving this strategy into RNA sequencing to identify aberrant slice isoforms, allele-specific expression and cryptic fusions in addition to point mutations. The ultimate goal is to combine a toolbox of technologies for precise genomic characterization of individual cancers with machine learning to improve molecular diagnostics, risk stratification, therapeutic selection and outcomes for children with cancer.

This activity has been approved for AMA PRA Category 1 Credit

For more information, or to register, please visit: Innovative Discoveries Series.